相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study
Bruce A. Hug et al.
CLINICAL THERAPEUTICS (2020)
TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings
Maryam A. Shetab Boushehri et al.
MOLECULAR PHARMACEUTICS (2018)
The Role of Toll-Like Receptor in Inflammation and Tumor Immunity
Xiaohong Cen et al.
FRONTIERS IN PHARMACOLOGY (2018)
INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.
Eric Angevin et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Dual character of Toll-like receptor signaling: Pro-tumorigenic effects and anti-tumor functions
Li Yu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2013)
Aggregation behavior of an ultra-pure lipopolysaccharide that stimulates TLR-4 receptors
Hirotaka Sasaki et al.
BIOPHYSICAL JOURNAL (2008)
Critical aspects of the Bayesian approach to phase I cancer trials
Beat Neuenschwander et al.
STATISTICS IN MEDICINE (2008)
Structural polymorphism and endotoxic activity of synthetic phospholipid-like amphiphiles
K Brandenburg et al.
BIOCHEMISTRY (2004)
Aggregates are the biologically active units of endotoxin
M Mueller et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
